HAS2在胶质母细胞瘤中的表达及与预后、免疫细胞浸润的相关性研究  

Expression of HAS2 in glioblastoma and its correlation with prognosis and immune cell infiltration

作　　者：孟磊[1] 王向阳 胡朝帅 申法政[1] 赵新利[1] Meng Lei;Wang Xiangyang;Hu Chaoshuai;Shen Fazheng;Zhao Xinli(Department of Neurosurgery,the First Affiliated Hospital of Xinxiang Medical University,Weihui,Henan 453000,China)

机构地区：[1]新乡医学院第一附属医院神经外科,河南卫辉453000

出　　处：《齐齐哈尔医学院学报》2023年第22期2101-2106,共6页Journal of Qiqihar Medical University

基　　金：2020年度河南省医学科技攻关计划联合共建项目(LHGJ20200510);2021年度河南省医学科技攻关计划联合共建项目(LHGJ20210515);2020年新乡医学院第一附属医院青年培育基金项目(QN-2020-B07)。

摘　　要：目的 探讨HAS2在胶质母细胞瘤中的表达及临床价值。方法 TCGA数据库中下载胶质母细胞瘤的转录组学数据,分析HAS2在胶质母细胞瘤中的表达及其与预后的关系,筛选胶质母细胞瘤中与HAS2的共表达基因并进行GO和KEGG富集分析,分析HAS2与免疫细胞浸润程度的相关性。纳入胶质母细胞瘤组织和癌旁组织,采用q-PCR和Western blot法检测并比较癌组织和癌旁组织中HAS2 mRNA和蛋白表达水平的差异。结果 HAS2在胶质母细胞瘤组织中的表达水平明显高于正常对照组,差异具有统计学意义(P<0.001);与TP53野生型相比,TP53突变型的胶质母细胞瘤患者HAS2的表达水平明显升高(P<0.05)。与低表达组相比,胶质母细胞瘤HAS2高表达组生存率明显降低(HR=1.6,P=0.013)。胶质母细胞瘤中与HAS2共表达基因富集的MF包括NADH脱氢酶活性,BP包括线粒体ATP合成,CC包括线粒体内膜,KEGG包括氧化磷酸化、PI3K-Akt信号通路等。HAS2与B细胞(r=0.428,P<0.001)、CD8~+T细胞(r=0.121,P<0.001)、CD4+T细胞(r=0.478,P<0.001)、巨噬细胞(r=0.454,P<0.001)、中性粒细胞(r=0.456,P<0.001)浸润程度均呈正相关性。与癌旁组织相比,胶质母细胞瘤组织中HAS2 mRNA和蛋白表达水平明显升高[(1.14±0.23)vs.(0.43±0.10),t=4.903,P=008]、[(0.86±0.11)vs.(0.06±0.01),t=12.545,P<0.001]。结论 HAS2与胶质母细胞瘤患者临床预后相关,可能作为胶质母细胞瘤治疗的一个潜在靶点。Objective To investigate the expression of HAS2 in glioblastoma and its clinical value.Methods The transcriptomic data of glioblastoma were downloaded from TCGA database,and the expression level of HAS2 in glioblastoma and its relationship with prognosis was analyzed.The co-expression genes of HAS2 in glioblastoma were screened by GO and KEGG enrichment analysis.The correlation between HAS2 and the infiltration degree of immune cells were analyzed.Glioblastoma tissue and paracancer tissue were included,the expression levels of HAS2 mRNA and protein in glioblastoma and adjacent tissues were detected by q-PCR and Western blot,respectively.Results The expression level of HAS2 in glioblastoma tissues was significantly higher than that in normal group(P<0.001).Compared with TP53 wild type,the expression level of HAS2 in glioblastoma patients with TP53 mutant was significantly increased(P<0.05).Compared with the HAS2 low-expression group,the survival rate of patients in the HAS2 high-expression group was significantly decreased(HR=1.6,P=0.013).In glioblastoma,co-expression genes of HAS2 enriched in MF,BP,CC and KEGG including NADH dehydrogenase activity,mitochondrial ATP synthesis coupled proton transport,mitochondrial inner membrane,oxidative phosphorylation and PI3K-Akt signaling pathway.HAS2 was positively correlated with B cells(r=0.428,P<0.001),CD8+T cells(r=0.121,P<0.001),CD4+T cells(r=0.478,P<0.001),macrophages(r=0.454,P<0.001),neutrophils(r=0.456,P<0.001).Compared with adjacent tissues,HAS2 mRNA and protein expression levels in glioblastoma tissues were significantly increased[(1.14±0.23)vs.(0.43±0.10),t=4.903,P=0.008;(0.86±0.11)vs.(0.06±0.01),t=12.545,P<0.001].Conclusions HAS2 is associated with the clinical prognosis of glioblastoma patients,which can be used as a potential therapy target in glioblastoma.

关 键 词：胶质母细胞瘤 HAS2 生存率 代谢 免疫细胞浸润 

分 类 号：R739.4[医药卫生—肿瘤]